Treatment-related myelodysplasia following fludarabine combination chemotherapy

被引：1

作者：

Tam, Constantine S. ^{[1
,2
]}

Seymour, John F. ^{[1
,3
]}

Prince, H. Miles ^{[1
]}

Kenealy, Melita ^{[1
]}

Wolf, Max ^{[1
]}

Januszewicz, E. Henry ^{[1
]}

Westerman, David ^{[1
,4
]}

机构：

[1] Peter MacCallum Canc Ctr, Haematol Dept, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia

[2] Alfred Hosp, Haematol Dept, Melbourne, Australia

[3] Univ Melbourne, Melbourne, Australia

[4] Peter MacCallum Canc Ctr, Pathol Dept, Melbourne, Australia

来源：

HAEMATOLOGICA | 2006年 / 91卷 / 11期

关键词：

purine analog; chemoimmunotherapy; chronic lymphocytic leukemia; follicular lymphoma; Waldenstrom's macroglobulinemia;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair. Among 137 patients treated with fludarabine combination regimens, ten patients developed MDS/sAML, including one who had received no other therapy. Six patients had abnormalities of chromosomes 5 and/or 7. The crude rate of MDS/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy.

引用

收藏

页码：1546 / 1550

页数：5

相关论文

共 45 条

[41] Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication? [J].

Cohen, Y ;

Da'as, N ;

Libster, D ;

Amir, G ;

Berrebi, A ;

Polliack, A .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 68 (02) :80-83

[42] Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005 [J].

Henry G Kaplan ;

Judith A Malmgren ;

Mary K Atwood .

BMC Cancer, 11

[43] Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma [J].

Kobayashi, Hiroyuki ;

Yamaguchi, Shigeru ;

Motegi, Hiroaki ;

Kaneko, Sadahiro ;

Endou, Shogo ;

Onimaru, Rikiya ;

Terasaka, Shunsuke ;

Houkin, Kiyohiro .

JOURNAL OF CHEMOTHERAPY, 2019, 31 (01) :35-41

[44] Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses [J].

Gristina, Valerio ;

Galvano, Antonio ;

Castellana, Luisa ;

Insalaco, Lavinia ;

Cusenza, Stefania ;

Graceffa, Giuseppa ;

Iacono, Federica ;

Barraco, Nadia ;

Castiglia, Marta ;

Perez, Alessandro ;

Rizzo, Sergio ;

Russo, Antonio ;

Bazan, Viviana .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

[45] Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163 [J].

Lapuc, Izabela ;

Bolkun, Lukasz ;

Eljaszewicz, Andrzej ;

Rusak, Malgorzata ;

Luksza, Ewa ;

Singh, Paulina ;

Miklasz, Paula ;

Piszcz, Jaroslaw ;

Ptaszynska-Kopczynska, Katarzyna ;

Jasiewicz, Malgorzata ;

Kaminski, Karol ;

Dabrowska, Milena ;

Bodzenta-Lukaszyk, Anna ;

Kloczko, Janusz ;

Moniuszko, Marcin .

ONCOLOGY REPORTS, 2015, 34 (03) :1269-1278

← 1 2 3 4 5 →